The cancer pain market size was valued at USD 6.53 billion in 2023, driven by increasing cancer incidence and rising demand for effective therapeutics to manage cancer pain across the 8 major markets. The market is expected to grow at a CAGR of 6.10% during the forecast period of 2024-2032, with the values likely to rise from USD 6.93 billion in 2024 to USD 11.12 billion by 2032.
Cancer pain is a complex and multidimensional symptom that affects the quality of life of cancer patients. Cancer pain can be caused by the tumor itself, the treatments, or the side effects of the treatments. Cancer pain can be acute or chronic, and can vary in intensity, frequency, and duration. The management of cancer pain involves a multidisciplinary approach that includes pharmacological and non-pharmacological interventions, such as opioids, non-opioids, adjuvants, nerve blocks, radiotherapy, surgery, psychological therapies, and complementary therapies.
Key Drivers and Constraints
The key drivers of the global cancer pain market are:
- The increasing prevalence and incidence of cancer worldwide, especially in the aging population.
- The rising awareness and demand for effective pain management among cancer patients and caregivers.
- The development and launch of novel and innovative products, such as extended-release formulations, transdermal patches, and abuse-deterrent formulations, that offer better efficacy, safety, and convenience.
- The expansion of the indications and the patient population for existing products, such as opioids, adjuvants, and cannabinoids.
- The favorable reimbursement policies and government initiatives that support the access and affordability of cancer pain treatments.
The key constraints of the global cancer pain market are:
- The high cost and low availability of some of the cancer pain treatments, especially in the developing and underdeveloped regions.
- The stringent regulatory requirements and the long approval process for new products and indications.
- The lack of standardized guidelines and protocols for cancer pain assessment and management across different regions and settings.
- The low awareness and education among healthcare professionals and patients about the optimal use of cancer pain treatments.
- The social stigma and legal barriers associated with some of the cancer pain treatments, such as opioids and cannabinoids.
Get a Free Sample Report with a Table of Contents: https://www.expertmarketresearch.com/reports/cancer-pain-market/requestsample
Key Trends and Developments
| Trend | Description |
| Increasing adoption of personalized and precision medicine approaches | Personalized and precision medicine aims to tailor the treatment and management of cancer pain according to the individual characteristics, preferences, and needs of each patient. This may involve the use of biomarkers, genomics, pharmacogenomics, or other molecular and genetic tests to identify the most effective and safe therapies for each patient. |
| Growing use of digital and mobile technologies | Digital and mobile technologies can help improve the access, delivery, and monitoring of cancer pain treatments, especially for patients who live in remote or underserved areas. For example, telemedicine, e-health, and m-health platforms can enable patients to consult with their healthcare providers, receive prescriptions, and access educational and supportive resources online. |
| Increasing awareness and education among healthcare professionals and patients | There is a need to increase the awareness and education among healthcare professionals and patients about the optimal use of cancer pain treatments, especially for those that face social stigma and legal barriers, such as opioids and cannabinoids. Healthcare professionals need to be trained and updated on the best practices and guidelines for assessing, diagnosing, treating, and monitoring cancer pain, as well as the benefits and risks of different therapeutic options. |
Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/cancer-pain-market
Market Segmentation
| Segment | Categories | Description |
| Drug Type | Opioids (Fentanyl, Morphine, Others), Non-Opioids (Acetaminophen, Non-Steroidal Anti-Inflammatory Drug), Nerve Blockers | Opioids manage moderate to severe pain. Non-opioids reduce inflammation and block pain without targeting opioid receptors. Nerve blockers interrupt pain transmission signals. |
| Indication Type | Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others | Includes major cancer types fueling the market share. The prevalence of various cancers is a primary market driver. |
| Treatment Type | Immunotherapy, Chemotherapy, Targeted Therapy, Hormonal Therapy | Comprises different treatment types each with unique mechanisms and potential side effects. |
| Region | United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, India | Covers major markets with significant growth forecast. North America leads due to a rising geriatric population, advanced healthcare, and high cancer prevalence. |
Competitive Landscape
The market report encompasses comprehensive analyses, including patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, as well as partnerships and collaborations analysis conducted by the leading key players in the market. Among the major companies contributing to this market are Eli Lilly, HISAMITSU PHARMACEUTICAL CO., INC., Aoxing Pharmaceutical Company, Inc., GRÜNENTHAL PHARMA GmbH & CO. KG, PFIZER INC., BIODELIVERY SCIENCES INTERNATIONAL, INC., OREXO AB, Johnson and Johnson, Medtronic plc, Novartis AG, and Glaxo SmithKline Plc. These analyses and the involvement of these prominent players highlight the dynamic and evolving nature of the market, underlining the significant investments and collaborations driving advancements and growth in the field.
Here is some major company associated news.
| Company | Products | Recent News |
| Pfizer Inc. | OxyContin, Embeda, Fentora, Lyrica | January 2020: Completed acquisition of Array BioPharma Inc. |
| Johnson & Johnson | Duragesic, Nucynta, Zytiga | December 2019: Launched Erleada (apalutamide) in the European Union |
| Teva Pharmaceutical Industries Ltd. | Actiq, Fentora, Cephalon | November 2019: Launched generic version of Fentora in the United States |
| Purdue Pharma L.P. | OxyContin, Butrans, Hysingla | October 2019: Filed for Chapter 11 bankruptcy protection |
| Mallinckrodt plc | Exalgo, Roxicodone, Xartemis | September 2019: Agreed to sell BioVectra Inc. to H.I.G. Capital for USD 250 million |
Read more report:
Myocarditis Market – https://www.expertmarketresearch.com/reports/myocarditis-market
Pulse lavage market – https://www.expertmarketresearch.com/reports/pulse-lavage-market
Telemedicine Market – https://www.expertmarketresearch.com/reports/telemedicine-market
About Us:
Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.
Our high-quality, data-driven analyses provide the essential framework for organizations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organization remains agile, proactive, and poised for success in today’s competitive market.
Don’t miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organization’s future success by acquiring one of our Expert Market Research reports today.
Media Contact:
Company Name: Claight Corporation
Contact Person: Robin Johnson, Business Consultant
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
